<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30209119</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1528-0020</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>132</Volume>                    <Issue>18</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Blood</Title>                <ISOAbbreviation>Blood</ISOAbbreviation>            </Journal>            <ArticleTitle>How I treat breast implant-associated anaplastic large cell lymphoma.</ArticleTitle>            <Pagination>                <MedlinePgn>1889-1898</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2018-03-785972</ELocationID>            <Abstract>                <AbstractText>Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently described form of T-cell non-Hodgkin lymphoma now formally recognized by the World Health Organization classification of lymphoid neoplasms. The disease most often presents with a delayed seroma around the breast implant, almost exclusively with a textured surface, and manifests with breast pain, swelling or asymmetry, capsular contracture, but can also present with a breast mass, and lymph node involvement. The prognosis of BIA-ALCL is favorable compared with many other subtypes of systemic T-cell lymphoma; however, unlike other non-Hodgkin lymphomas, complete surgical excision for localized disease is an important part of the management of these patients. In this paper, we share our recommendations for a multidisciplinary team approach to the diagnosis, workup, and treatment of BIA-ALCL in line with consensus guidelines by the National Comprehensive Cancer Network.</AbstractText>                <CopyrightInformation>Â© 2018 by The American Society of Hematology.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mehta-Shah</LastName>                    <ForeName>Neha</ForeName>                    <Initials>N</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5744-0670</Identifier>                    <AffiliationInfo>                        <Affiliation>Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Clemens</LastName>                    <ForeName>Mark W</ForeName>                    <Initials>MW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Plastic Surgery, MD Anderson Cancer Center, Houston, TX; and.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Horwitz</LastName>                    <ForeName>Steven M</ForeName>                    <Initials>SM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Blood</MedlineTA>            <NlmUniqueID>7603509</NlmUniqueID>            <ISSNLinking>0006-4971</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30209119</ArticleId>            <ArticleId IdType="pii">blood-2018-03-785972</ArticleId>            <ArticleId IdType="doi">10.1182/blood-2018-03-785972</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>